WilmerHale Advises Underwriters in Follow-on Public Offering of Viridian Therapeutics

WilmerHale Advises Underwriters in Follow-on Public Offering of Viridian Therapeutics

Client News

WilmerHale represented the underwriters in the follow-on public offering of 7,142,858 shares of common stock of Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. The shares of common stock were issued at a public offering price of $21.00 per share. The gross proceeds to Viridian were $150 million, before deducting underwriting discounts, commissions and offering expenses. The offering priced on January 17, 2024 and closed on January 22, 2024.

The WilmerHale team representing the underwriters consisted of Lisa Firenze, Molly Fox, Katharine Patterson and Milan Kumar, with assistance from Bruce Manheim and Barish Ozdamar.